Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Cortez Castedo

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Ecancermedicalscience|January 28, 2015
Metronomics for thymic carcinomaJacobo Muñoz Del Toro, Patricia Cortez Castedo, Alfonso Cortés Salgado, et al.
Breast Cancer Research : BCR|August 7, 2025
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trialElena López-Miranda, Jose Manuel Pérez-García, María Gión, et al.
Nature Medicine|June 4, 2025
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trialMaría Gion, Isabel Blancas, Patricia Cortez-Castedo, et al.
Eclinicalmedicine|April 19, 2024
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/<i>PIK3CA</i>-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trialAntonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Ecancermedicalscience|January 28, 2015
Metronomics for thymic carcinomaJacobo Muñoz Del Toro, Patricia Cortez Castedo, Alfonso Cortés Salgado, et al.
Breast Cancer Research : BCR|August 7, 2025
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trialElena López-Miranda, Jose Manuel Pérez-García, María Gión, et al.
Nature Medicine|June 4, 2025
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trialMaría Gion, Isabel Blancas, Patricia Cortez-Castedo, et al.
Eclinicalmedicine|April 19, 2024
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/<i>PIK3CA</i>-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trialAntonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, et al.
Pageof 1